The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications

Please use this link to access this publication. Abstract Purpose  Increased cannabis use and recent drug approvals pose new challenges for avoiding drug interactions between

October 7, 2024

The potential for medicinal cannabis to help manage challenging behaviour in people with intellectual disability: A perspective review

Abstract Background: Around 2% of the population have intellectual disabilities. Over one-third people with intellectual disabilities (PwID) present with ‘challenging behaviour’, which nosologically and diagnostically is

September 5, 2024

The Place of Cannabinoids in the Treatment of Gynecological Pain

Abstract Cannabis sativa (L), a plant with an extensive history of medicinal usage across numerous cultures, has received increased attention over recent years for its therapeutic

December 7, 2023

The Pharmacology of Cannabinoids in Chronic Pain

Abstract Background: Our objective was to provide an overview of the currently available scientific and clinical data supporting the use of Cannabis and Cannabis-derived products for the treatment of

February 1, 2026

The Pharmacological Case for Cannabigerol

ABSTRACT   Medical cannabis and individual cannabinoids, such as D9- tetrahydrocannabinol (D9-THC) and cannabidiol (CBD), are receiving growing attention in both the media and the

July 13, 2021

The Pharmacological Basis of Cannabis Therapy for Epilepsy

Recently, cannabis has been suggested as a potential alternative therapy for refractory epilepsy, which affects 30% of epilepsy, both adults and children, who do not

September 19, 2019

The Pharmacologic and Clinical Effects of Medical Cannabis

Cannabis, or marijuana, has been used for medicinal purposes for many years. Several types of cannabinoid medicines are available in the United States and Canada.

The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial

Abstract Background Precise cannabis treatment dosing remains a major challenge, leading to physicians’ reluctance to prescribe medical cannabis. Objective To test the pharmacokinetics, analgesic effect,

July 2, 2024

The Pharmacokinetics and Pharmacodynamics of a Hemp-Derived “Full-Spectrum” Oral Cannabinoid Product with a 1:1 Ratio of Cannabidiol to Cannabidiolic Acid and Delta-9-Tetrahydrocannabinol to Delta-9-Tetrahydrocannabinolic Acid: A Double-Blind, Placebo-Controlled, Within-Subjects Human Laboratory Study

Abstract Aim: To examine the acute pharmacokinetics (PK) and pharmacodynamics (PD) of a patented oral cannabinoid product containing a botanical hemp-derived “full-spectrum” extract with an

March 22, 2026

The Pharmacogenetics of Cannabis in the Treatment of Chronic Pain

Abstract Background: The increase in the medical use of cannabis has revealed a number of beneficial effects, a variety of adverse side effects and great

March 14, 2024